title: Cap formation on lymphocytes from patients with leukemic diseases induced by four different lectins.
abstract: When ficoll purified peripheral blood lymphocytes were treated with fluorescein conjugated lectins from lentils (LCH), castor beans (RCA) and phaseolus coccineus beans (L-and E-PHA) for 15 min and the percentages of the cap forming cells were examined, the values of leukemic lymphocytes were reduced compared to the values obtained with normal lymphocytes. The reduction was more than half in patients with acute and chronic myelogenous leukemia and immunoblastoma, it was only one quarter in patients with chronic lymphocytic leukemia, Hodgkin's disease and lymphosarcoma. The lowest number of cap forming cells was found in lymphoblasts of established lymphoblastoid cell lines. The four different lectins showed nearly the same capacity in the induction of caps. After successive binding, the different lectins showed cocapping on the lymphocyte surface.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002367:Ricinus communis; D007887:Fabaceae; D006689:Hodgkin Disease / Q000097:blood; D006801:Humans; D037102:Lectins / Q000494:pharmacology*; D007938:Leukemia / Q000097:blood*; D007945:Leukemia, Lymphoid / Q000097:blood; D007951:Leukemia, Myeloid / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000097:blood; D008214:Lymphocytes / Q000187:drug effects*; D008223:Lymphoma / Q000097:blood*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood; D008875:Middle Aged; D037121:Plant Lectins; D010946:Plants, Medicinal; D010947:Plants, Toxic
chemical_list: D037102:Lectins; D037121:Plant Lectins
references.citation: J Exp Med. 1972 Oct 1;136(4):885-906
references.pmid: 4626851
references.citation: Int J Cancer. 1976 Apr 15;17(4):448-54
references.pmid: 1279037
references.citation: Nat New Biol. 1971 Oct 20;233(42):225-9
references.pmid: 20480991
references.citation: Biochim Biophys Acta. 1973 Feb 21;295(2):582-94
references.pmid: 4633532
references.citation: J Exp Med. 1974 Apr 1;139(4):957-68
references.pmid: 4131515
references.citation: J Immunol. 1975 May;114(5):1532-6
references.pmid: 1079038
references.citation: Experientia. 1972 Jan 15;28(1):84-5
references.pmid: 5062493
references.citation: Int J Cancer. 1975 Feb 15;15(2):253-9
references.pmid: 1126758
references.citation: Eur J Biochem. 1972 Nov 7;30(3):571-8
references.pmid: 4674295
references.citation: Int J Cancer. 1977 Mar 15;19(3):345-50
references.pmid: 300366
references.citation: FEBS Lett. 1976 Jul 15;66(2):215-20
references.pmid: 955082
references.citation: Proc Natl Acad Sci U S A. 1975 Mar;72(3):1046-9
references.pmid: 1055364
references.citation: J Immunol Methods. 1972 May;1(3):289-301
references.pmid: 4561342
references.citation: J Biol Chem. 1971 Nov;246(21):6581-6
references.pmid: 5132671
references.citation: Science. 1976 Apr 16;192(4236):218-26
references.pmid: 769162
references.citation: Eur J Biochem. 1973 Sep 21;38(1):193-200
references.pmid: 4204294
references.citation: J Clin Invest. 1975 Jan;55(1):84-93
references.pmid: 1088910
references.citation: J Biol Chem. 1971 Mar 25;246(6):1590-5
references.pmid: 4993956
references.citation: Prog Med Virol. 1975;21:177-87
references.pmid: 174153
references.citation: Cell Immunol. 1976 Sep;26(1):21-8
references.pmid: 1085655